Ophthotech to Present at 30th Annual J.P. Morgan Healthcare Conference

January 3, 2012

Download PDF

Princeton, NJ and New York, NY – January 3, 2012 – Ophthotech Corp. announced today that the company will participate in the 30th Annual J.P. Morgan Healthcare Conference in San Francisco. Samir Patel, M.D., co-founder, president and chief executive officer of Ophthotech, will deliver a presentation on Jan. 11, 2012, at 10:30 a.m. PST in presentation room Elizabethan C/D at the Westin St. Francis Hotel, San Francisco.

Ophthotech is focused on developing and commercializing therapies for age-related macular degeneration (AMD), an expanding, multi-billion dollar therapeutic area. The company’s lead product candidate, an anti-PDGF agent (E10030), is the first therapy to demonstrate both disease modification and significant visual gain in the majority of patients with wet AMD when co-administered with an anti-VEGF agent. Wet AMD remains a major unmet need as most patients fail to gain significant vision with monotherapy using an anti-VEGF agent, the current standard of care. A highly powered 445-patient Phase 2b trial of E10030 is fully enrolled, with results expected in the first half of 2012.

Ophthotech Corp. is a privately held biopharmaceutical company based in Princeton, NJ and New York, NY focused on developing and commercializing therapies for dry and wet AMD. Ophthotech is developing a pipeline of compounds with strong scientific foundations for the treatment of AMD, with the goal of bringing them to market in an accelerated manner. For more information, please visit www.ophthotech.com.

Tom Biancardi
Ophthotech Corp.
VP, Finance and Operations

Jennifer Devine
SmithSolve LLC
On behalf of Ophthotech Corp.
973-442-1555 ext. 102

Information for Patients
If you have been recently diagnosed with a retinal condition by your eye care professional, please visit the link below.
Learn More